Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03570749 · OUTCOME

Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percent change
Interval / dispersion
Standard Deviation
Time frame
Baseline, Week 52

What was measured

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes.

Analysis population: All randomized phase 3 open-label addendum participants who had evaluable data for this outcome measure.

Groups in this outcome

4 mg Baricitinib Phase 3 Open-Label Addendum

Participants who received one 4 mg Baricitinib tablet administered orally QD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
4 mg Baricitinib Phase 3 Open-Label Addendum11

Reported measurements

Source class 1
Values in percent change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
4 mg Baricitinib Phase 3 Open-Label Addendum-40.4433.182Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        33.182
        value
        -40.44
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
description
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes.
dispersion Type
Standard Deviation
groups
  1. description
    Participants who received one 4 mg Baricitinib tablet administered orally QD.
    id
    OG000
    title
    4 mg Baricitinib Phase 3 Open-Label Addendum
param Type
MEAN
population Description
All randomized phase 3 open-label addendum participants who had evaluable data for this outcome measure.
reporting Status
POSTED
time Frame
Baseline, Week 52
title
Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum
type
PRIMARY
unit Of Measure
percent change

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice